191 related articles for article (PubMed ID: 21756237)
1. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
4. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of malignancy-associated hypercalcemia.
Lumachi F; Brunello A; Roma A; Basso U
Curr Med Chem; 2008; 15(4):415-21. PubMed ID: 18288996
[TBL] [Abstract][Full Text] [Related]
6. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hypercalcemia.
Camozzi V; Luisetto G; Basso SM; Cappelletti P; Tozzoli R; Lumachi F
Med Chem; 2012 Jul; 8(4):556-63. PubMed ID: 22571196
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
[TBL] [Abstract][Full Text] [Related]
9. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
11. Cancer-induced hypercalcemia.
Lumachi F; Brunello A; Roma A; Basso U
Anticancer Res; 2009 May; 29(5):1551-5. PubMed ID: 19443365
[TBL] [Abstract][Full Text] [Related]
12. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of malignancy-associated hypercalcemia].
Endo I; Inoue D
Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
[TBL] [Abstract][Full Text] [Related]
14. [The significance of early diagnosis of cancer-related hypercalcaemia].
Radványi I; Csikós A; Balogh S
Orv Hetil; 2013 Sep; 154(35):1367-73. PubMed ID: 23974972
[TBL] [Abstract][Full Text] [Related]
15. [Tumoral hypercalcemia: physiopathology and treatment].
Rizzoli R; Jung A; Bonjour JP
Schweiz Med Wochenschr; 1985 Mar; 115(10):326-32. PubMed ID: 3157214
[TBL] [Abstract][Full Text] [Related]
16. [Hypercalcemia of malignancy: clinical features, diagnosis and treatment].
Farias ML
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):816-24. PubMed ID: 16444366
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
19. [Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia].
Okazaki R
Clin Calcium; 2010 Oct; 20(10):1497-502. PubMed ID: 20890031
[TBL] [Abstract][Full Text] [Related]
20. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
